Research Articles | Page 28 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Apr 2024 Haematologica Aplastic Anemia
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria Jan 2020 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)
Granulocyte transfusions in severe aplastic anemia Dec 2023 Haematologica Aplastic Anemia
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial Apr 2025 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)
Long term survivors in severe aplastic anemia: standard mortality rates now comparable to controls? Jul 2023 Haematologica Aplastic Anemia
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia Jun 2020 Haematologica Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia. Feb 2019 Haematologica Aplastic Anemia
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Aug 2024 Haematologica Aplastic Anemia
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes Apr 2023 Haematologica Myelodysplastic Syndromes (MDS)
Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial Nov 2024 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)